British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders

@article{Wilson2010BritishAF,
  title={British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders},
  author={Sj Wilson and D. J. Nutt and Chris Alford and SV Argyropoulos and D. Baldwin and AN Bateson and T Britton and Catherine Crowe and Derk-Jan Dijk and Carolyn Espie and Paul Gringras and Goeran Hajak and C. Idzikowski and AD Krystal and JR Nash and Hugh Selsick and Al Sharpley and A. Wade},
  journal={Journal of Psychopharmacology},
  year={2010},
  volume={24},
  pages={1577 - 1601}
}
Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners. These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment. A consensus meeting was held in London in May 2009. Those… 

Figures and Tables from this paper

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: An update

This British Association for Psychopharmacology guideline replaces the original version published in 2010, and contains updated information and recommendations. A consensus meeting was held in London

Issues and challenges in implementing clinical practice guideline for the management of chronic insomnia

  • C. Morin
  • Medicine, Psychology
    Journal of sleep research
  • 2017
There is consensus in the scientific and professional sleep community that CBT should be the treatment of choice for chronic insomnia, but there is still a major gap between reaching consensus at the organizational level and adopting/implementing evidence-based recommendations at the individual clinical practice level.

Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline.

This guideline provides recommendations for making decisions about when and how to reduce the dose of or stop antipsychotics, and suggests patients and caregivers might be more amenable to deprescribing if they understand the rationale, are involved in developing the tapering plan, and are offered behavioural advice or management.

Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies

It is suggested that symptoms of insomnia must always be assessed in the Italian clinical practice by evaluating nocturnal and daytime symptoms, comorbid conditions and lifestyle.

Deprescribing benzodiazepine receptor agonists: Evidence-based clinical practice guideline.

This guideline provides recommendations for making decisions about when and how to reduce and stop BZRAs and suggests patients might be more amenable to deprescribing conversations if they understand the rationale, are involved in developing the tapering plan, and are offered behavioural advice.

Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice

A group of young Italian psychiatrists attempted to highlight possible flaws in current teaching pathways, identify the main clinical pros and cons regarding current use of BDZs in clinical practice, and provide an updated overview of their use across specific clinical areas and patient populations.

Eszopiclone for insomnia.

Meta-analytic integrations of participant-reported data on sleep efficacy outcomes demonstrated better results for eszopiclone compared to placebo; there were no significant changes from baseline to the first three nights after drug discontinuation for sleep onset latency.

La melatonina en insomnio primario: ¿ qué evidencias?

There is sufficient evidence to recommend the use of melatonin for symptomatic relief of primary insomnia and improvement in quality of life (SOR B), however, further studies with rigorous methodologies and long-term monitoring are needed to obtain more consistent results.

Pharmacological Treatment of Insomnia

Improvement in the management of insomnia will result from systematic research with these drugs, with drugs in development, and with novel therapeutic approached, such as combined therapies.

Melatonina na insônia primária: Quais as evidências?

There is sufficient evidence to recommend the use of melatonin for symptomatic relief of primary insomnia and improvement in quality of life (SOR B), however, further studies with rigorous methodologies and long-term monitoring are needed to obtain more consistent results.
...

References

SHOWING 1-10 OF 284 REFERENCES

Evidence-Based Guidelines for Treating Bipolar Disorder: Recommendations from the British Association for Psychopharmacology

  • G. Goodwin
  • Medicine, Psychology
    Journal of psychopharmacology
  • 2003
The guidelines cover the diagnosis of bipolar disorder, clinical management and strategies for the use of medicines in short-term treatment of episodes, relapse prevention and stopping treatment.

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

These British Association for Psychopharmacology guidelines cover the diagnosis of anxiety disorders and key steps in clinical management, including acute treatment, relapse prevention and approaches for patients who do not respond to first-line treatments.

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology.

  • G. Goodwin
  • Psychology, Medicine
    Journal of psychopharmacology
  • 2009
The British Association for Psychopharmacology guidelines specify the scope and target of treatment for bipolar disorder, and are presented as recommendations to aid clinical decision making for practitioners: they may also serve as a source of information for patients and carers.

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines

These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment.

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.

The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.

Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology

Although the consensus statement dealt largely with medication, the role of dementia care in secondary services (geriatric medicine and old age psychiatry) and primary care, along with health economics, was discussed.

EFNS guidelines on management of narcolepsy

A task force composed of the leading specialists of narcolepsy in Europe conducted an extensive review of pharmacological and behavioral trials available in the literature to reinforce the use of those drugs evaluated in randomized placebo‐controlled trials and to reach a consensus, as much as possible, on theUse of other available medications.

Eszopiclone for Insomnia

The results of the 5 available double-blind, placebo-controlled studies and 1 open-label, 6-month extension trial showed that eszopiclone was safe and effective in the treatment of transient and chronic insomnia in adult and geriatric patients.

Treatments for somnambulism in adults: assessing the evidence.

...